Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Harrow Q1 Earnings Call Highlights MarketBeat - Tue May 12, 10:10AM CDT

Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized...

HROW : 30.86 (+3.47%)
Harrow: Q1 Earnings Snapshot AP - Mon May 11, 3:37PM CDT

Harrow: Q1 Earnings Snapshot

HROW : 30.86 (+3.47%)
Harrow Announces First Quarter 2026 Financial Results GlobeNewswire - Mon May 11, 3:05PM CDT

First Quarter 2026 and Selected Highlights:  VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test Barchart - Fri May 8, 4:06PM CDT

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 30.86 (+3.47%)
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 GlobeNewswire - Mon Apr 27, 6:00AM CDT

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 30.86 (+3.47%)
Harrow Announces the Issuance of J-Code for IOPIDINE® 1% GlobeNewswire - Thu Apr 16, 6:00AM CDT

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE ® 1% (apraclonidine...

HROW : 30.86 (+3.47%)
LogiCare3PL Selected as Distribution Partner by Harrow PR Newswire - Tue Apr 14, 9:30AM CDT

OLIVE BRANCH, Miss. , April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic...

HROW : 30.86 (+3.47%)
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 GlobeNewswire - Tue Mar 24, 3:57PM CDT

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private...

HROW : 30.86 (+3.47%)

Barchart Exclusives

More Than 1,000 Corporate Positions Hit at Walmart in Latest Restructuring. What This Means for WMT Stock. Barchart - Thu May 14, 6:30PM CDT
Walmart is eliminating or relocating more than 1,000 corporate positions in its global technology, AI, e-commerce, and advertising teams as part of a restructuring aimed at reducing duplication and accelerating focus on AI and digital priorities, according to a May 12, 2026 internal memo. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.